Alex Martin

Mr. Martin has been a member of ESSA’s board since 2019 and is currently the Chairman of Veralox Therapeutics and Chief Executive Officer of Abcuro, a clinical stage biopharmaceutical company targeting highly cytotoxic T cells in autoimmune diseases. Mr. Martin brings more than 25 years of experience in senior executive roles in the life science industry, with a focus on business development, operations, and raising capital. Previously, Mr. Martin served as Chief Executive Officer at of Palladio Biosciences which was acquired by Centessa Pharmaceuticals, and prior to that he was Chief Executive Officer of Realm Therapeutics until acquired by ESSA. In his career, he has served as Chief Executive Officer of Affectis Pharmaceuticals, President of moksha8, Chief Operating Officer of Intercept Pharmaceuticals and Chief Finance Officer at Bioxell. Mr. Martin began his career at SmithKline Beecham Pharmaceuticals where he held roles of increasing responsibility in marketing and strategic product development, and later joined Novartis as Vice President, Global Business Development & Licensing.

Mr. Martin is a guest lecturer at Wharton and Columbia Business School on biotech, entrepreneurship, and financing. Mr. Martin holds a B.A. from Cornell University and an M.B.A. from Harvard.